Ionis Pharmaceuticals moves forward with FDA review of donidalorsen for HAE

Ionis Pharmaceuticals moves forward with FDA review of donidalorsen for HAE

In a significant development for hereditary angioedema (HAE) patients, Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for donidalorsen, an investigational RNA-targeted therapy designed to prevent HAE attacks in individuals aged 12 and older. The FDA has set a Prescription Drug User […]

Exicure’s stock explodes 78% overnight – but is the comeback for real?

Exicure’s stock explodes 78% overnight – but is the comeback for real?

Shares of biopharmaceutical company Exicure Inc. skyrocketed by 78% in after-hours trading, closing at $2.84. The surge came after Exicure announced a significant debt-for-equity exchange with two holders of promissory notes. This financial maneuver aims to stabilise the company’s precarious financial standing amid growing uncertainties. Exicure converts debt to equity amid financial turmoil Exicure Inc., […]

Convenience store giant Alimentation Couche-Tard to snap up GetGo Café + Market in mega deal

Convenience store giant Alimentation Couche-Tard to snap up GetGo Café + Market in mega deal

Alimentation Couche-Tard Inc. has announced a significant move in the convenience retail sector with its acquisition of GetGo Café + Market stores from Giant Eagle Inc. The deal, which is expected to finalize in 2025 subject to regulatory approvals, marks a major expansion for Couche-Tard in the U.S. market. GetGo Café + Market is renowned […]

How PETRONAS, Enilive, and Euglena’s biorefinery in Malaysia could redefine global energy markets

How PETRONAS, Enilive, and Euglena’s biorefinery in Malaysia could redefine global energy markets

Petroliam Nasional Berhad (PETRONAS), Enilive S.p.A, and Euglena Co., Ltd. have reached a major milestone with their final investment decision (FID) to develop a cutting-edge biorefinery within PETRONAS’ Pengerang Integrated Complex (PIC) in Johor, Malaysia. This ambitious project is set to significantly impact the biofuels sector, with operations expected to commence by the second half […]

InventisBio licenses lung cancer drug D-0316 to Betta Pharma in RMB230m deal

InventisBio licenses lung cancer drug D-0316 to Betta Pharma in RMB230m deal

In a significant development within the pharmaceutical industry, Shanghai-based InventisBio has entered into a strategic partnership with Betta Pharmaceuticals Co., Ltd. to co-develop the promising lung cancer drug D-0316. Under this agreement, InventisBio has out-licensed the rights to D-0316 in China, Hong Kong, and Taiwan to Betta Pharmaceuticals Co., Ltd. in a deal valued at […]